Allucent

Protecting the Primary Endpoint: Ensuring Data Integrity in Immunology & Inflammation Clinical Trials

Immunology and inflammation trial endpoints can be subjective, making them vulnerable to variability that can dilute treatment effects and inflate placebo response. Allucent protects these endpoints through standardized rater training, centralized blinded reads for imaging and histopathology, and…

AI Across the Clinical Trial Lifecycle

Click the image below to download the infographic. From protocol design and site selection to patient recruitment, trial operations, and data analysis, artificial intelligence (AI) and other emerging technologies are reshaping the future of clinical development, offering new opportunities to…

Oncology Trends: Clinical Trial Activity and Innovation Shifts in 2025

Oncology remained the leading area of clinical development in 2025, with continued investment in precision medicine and innovative therapeutic platforms despite a slight decline in overall trial activity. Growth in antibody-drug conjugates (ADCs), bispecific antibodies, radiopharmaceuticals, and…

Achieving Critical Database Lock Milestones in a Global Oncology Study

Study Background Allucent was selected to provide full-service support for a Phase IIb randomized clinical trial in patients with first line metastatic head and neck squamous cell carcinoma (HNSCC) for a leading global biopharma company. The global study was conducted across 31 sites in multiple…

Advancing Patient Selection in Oncology: Enrichment Strategies and Emerging Diagnostics

In the race to bring new oncology therapies to market, patient selection is more critical than ever. With narrow windows of exclusivity and mounting competitive pressure, biotech sponsors are rethinking their clinical development strategies -starting with smarter trial enrollment.  This live panel…

ASCO 2026 Highlights: Five Trends Shaping the Future of Oncology Drug Development

Each year, the ASCO Annual Meeting offers a glimpse into where oncology research is heading next. In 2026, the conversations extended beyond breakthrough data alone. This year’s meeting reflected a broader shift toward smarter, more adaptive, and increasingly personalized approaches to cancer…